title: Social cognition.
abstract: Social cognition is a major problem underlying deficiencies in interpersonal relationships in several psychiatric populations. And yet there is currently no gold standard for pharmacological treatment of psychiatric illness that directly targets these social cognitive areas. This chapter serves to illustrate some of the most innovative attempts at pharmacological modulation of social cognition in psychiatric illnesses including schizophrenia, borderline personality disorder, autism spectrum disorders, antisocial personality disorder and psychopathy, social anxiety disorder, and posttraumatic stress disorder. Pharmacological modulation includes studies administering oxytocin, ecstasy (MDMA), modafinil, methylphenidate, and D-cycloserine. Furthermore, some background on social cognition research in healthy individuals, which could be helpful in developing future treatments, is provided as well as the potential for each drug as a long-term treatment option.
authors.affiliation: Department of Psychiatry, University of Bonn, 53105, Bonn, Germany.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Patin
authors.forename: René
authors.initials: R
authors.lastname: Hurlemann
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D007398:Interpersonal Relations; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D018697:Nootropic Agents / Q000627:therapeutic use*; D012919:Social Behavior
chemical_list: D018697:Nootropic Agents